TW202140415A - 作為用於神經精神病症及疾病之疾病調節治療之右旋美沙酮(dextromethadone) - Google Patents

作為用於神經精神病症及疾病之疾病調節治療之右旋美沙酮(dextromethadone) Download PDF

Info

Publication number
TW202140415A
TW202140415A TW110100157A TW110100157A TW202140415A TW 202140415 A TW202140415 A TW 202140415A TW 110100157 A TW110100157 A TW 110100157A TW 110100157 A TW110100157 A TW 110100157A TW 202140415 A TW202140415 A TW 202140415A
Authority
TW
Taiwan
Prior art keywords
nmdar
dextromethadone
disorder
composition
administration
Prior art date
Application number
TW110100157A
Other languages
English (en)
Chinese (zh)
Inventor
保羅 L 曼弗雷蒂
查爾斯 E 因圖里西
馬丁 薩拉 德
雅各布 斯格裡格納尼
安德里亞 馬塔雷
安德魯 卡伐利
Original Assignee
義大利帕多瓦大學
瑞士生物醫學研究所
保羅 L 曼弗雷蒂
查爾斯 E 因圖里西
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 義大利帕多瓦大學, 瑞士生物醫學研究所, 保羅 L 曼弗雷蒂, 查爾斯 E 因圖里西 filed Critical 義大利帕多瓦大學
Publication of TW202140415A publication Critical patent/TW202140415A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
TW110100157A 2020-01-03 2021-01-04 作為用於神經精神病症及疾病之疾病調節治療之右旋美沙酮(dextromethadone) TW202140415A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202062956839P 2020-01-03 2020-01-03
US62/956,839 2020-01-03
US202062963874P 2020-01-21 2020-01-21
US62/963,874 2020-01-21
US202062993188P 2020-03-23 2020-03-23
US62/993,188 2020-03-23
US202063010391P 2020-04-15 2020-04-15
US63/010,391 2020-04-15
US202063031785P 2020-05-29 2020-05-29
US63/031,785 2020-05-29

Publications (1)

Publication Number Publication Date
TW202140415A true TW202140415A (zh) 2021-11-01

Family

ID=76687448

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110100157A TW202140415A (zh) 2020-01-03 2021-01-04 作為用於神經精神病症及疾病之疾病調節治療之右旋美沙酮(dextromethadone)

Country Status (12)

Country Link
US (1) US20230017786A1 (https=)
EP (1) EP4085044A4 (https=)
JP (2) JP2023509484A (https=)
KR (1) KR20220164470A (https=)
CN (1) CN115397804A (https=)
AU (1) AU2020419181A1 (https=)
BR (1) BR112022013160A2 (https=)
CA (1) CA3166254A1 (https=)
MX (1) MX2022007768A (https=)
TW (1) TW202140415A (https=)
UY (1) UY39007A (https=)
WO (1) WO2021138443A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119202724B (zh) * 2024-09-25 2025-05-30 宁夏医科大学总医院 一种脓毒症心肌病诊断模型的构建方法及诊断系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US9468611B2 (en) * 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
EP2906202A4 (en) * 2012-10-15 2016-04-27 Isa Odidi ORAL DRUG RELIEF FORMULATIONS
AU2018215056A1 (en) * 2017-01-31 2019-08-08 Charles E. Inturrisi D-methadone and its derivatives for use in the treatment of disorders of the nervous system
CA3064846A1 (en) * 2017-05-25 2018-11-29 Glytech, Llc Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
EP3917619A4 (en) * 2019-01-30 2022-10-26 University of Padova Structurally modified opioids for prevention and treatment of diseases and conditions

Also Published As

Publication number Publication date
JP2023509484A (ja) 2023-03-08
US20230017786A1 (en) 2023-01-19
WO2021138443A1 (en) 2021-07-08
EP4085044A1 (en) 2022-11-09
MX2022007768A (es) 2022-09-27
BR112022013160A2 (pt) 2022-11-08
UY39007A (es) 2021-07-30
KR20220164470A (ko) 2022-12-13
EP4085044A4 (en) 2024-06-12
CN115397804A (zh) 2022-11-25
CA3166254A1 (en) 2021-07-08
JP2026062924A (ja) 2026-04-10
AU2020419181A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
Tian et al. The molecular pathophysiology of depression and the new therapeutics
Johnston et al. Ketamine in neuropsychiatric disorders: an update
Kamp et al. Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature
Preti New developments in the pharmacotherapy of cocaine abuse
Mathew et al. Ketamine for treatment-resistant unipolar depression: current evidence
Mitchell et al. Good night and good luck: norepinephrine in sleep pharmacology
Fowler et al. Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice
Hayashi et al. An update on the development of drugs for neuropsychiatric disorders: focusing on the σ1 receptor ligand
Kim et al. The role of glutamate underlying treatment-resistant depression
A. Bullock et al. Pathological gambling: neuropsychopharmacology and treatment
Das Repurposing of drugs–the ketamine story
JP2021523228A (ja) 物質乱用の治療方法
Strong et al. NMDA receptor modulators: an updated patent review (2013–2014)
Bryant et al. Effects of repeated intravenous ketamine in treatment-resistant geriatric depression: a case series
US20230117508A1 (en) Enhancement of camp signaling as a combination drug strategy for the treatment of psychiatric and neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists
Jones Potential of glial cell modulators in the management of substance use disorders
Heilig Stress‐related neuropeptide systems as targets for treatment of alcohol addiction: A clinical perspective
Serretti Anhedonia: Current and future treatments
JP2026062924A (ja) 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン
Scala et al. The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
Rothman et al. Dual dopamine–5-HT releasers: potential treatment agents for cocaine addiction
Lékó et al. Approved, promising, and experimental medications for treatment of alcohol use disorder
Mansoori et al. Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity
Lee et al. Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy
Guan The role of trace amine-associated receptor 1 (TAAR1) in the pathophysiology and treatment of depression